SCHEMBL16291774

SCHEMBL16291774

O=C(O)c1ccnc(CN2CCCCC2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 7/20 0.74
▸ KDM5C P41229 3/20 0.74
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ HIF1A Q16665 1/20 0.56
▸ KDM2B Q8NHM5 1/20 0.53
▸ WNT1 P04628 1/20 0.45
▸ DYRK1A Q13627 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ KDM5A P29375 3/20 0.45
▸ KDM5B Q9UGL1 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KDM6B O15054 2/20 0.45
▸ KDM4A O75164 2/20 0.45
▸ KDM2A Q9Y2K7 2/20 0.45
▸ KDM3A Q9Y4C1 2/20 0.45
▸ TET3 O43151 1/20 0.45
▸ BBOX1 O75936 1/20 0.45
▸ ASPH Q12797 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2305288 0.98 KDM4C (0.76) KDM4CKDM5CCYP2D6CYP2C9HIF1A
SCHEMBL15636461 0.95 KDM4C (0.76) KDM4CKDM5CCYP2D6CYP2C9HIF1A
SCHEMBL2303795 0.85 KDM4C (0.71) KDM4CKDM5CKDM2BWNT1DYRK1A
SCHEMBL28441622 0.85 KDM4C (0.71) KDM4CKDM5CCYP2D6CYP2C9HIF1A
SCHEMBL19741663 0.82 KDM4C (0.56) KDM4CKDM5CCYP2D6CYP2C9HIF1A
SCHEMBL9736097 0.81 KDM4C (0.54) KDM4CKDM5CWNT1DYRK1AKDM4E
SCHEMBL21257752 0.80 KDM4C (0.54) KDM4CKDM5CCYP2D6CYP2C9HIF1A
SCHEMBL14825843 0.80 KDM5C (0.57) KDM4CKDM5CKDM4EALDH1A1
SCHEMBL17144722 0.80 KDM4C (0.56) KDM4CKDM5CCYP2D6CYP2C9HIF1A
SCHEMBL24214180 0.79 KDM4C (0.63) KDM4CKDM5CKDM2BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10221139-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
US-10189787-B2 Inhibitors of histone demethylases GILEAD SCIENCES, INC. (US) 2019-01-29 — — US disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
EP-3023415-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2017-12-06 — — EP disclosed
CN-107434803-A Histone demethylase inhibitor 吉利德科学公司 2017-12-05 — — CN disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2017-11-09 — — US disclosed
EP-2903968-B1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES INC (US) 2016-12-07 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
EP-3023415-A1 INHIBITORS OF HISTONE DEMETHYLASES Epitherapeutics ApS (DK) 2016-05-25 — — EP disclosed
CN-104981458-A Inhibitors of histone demethylases EPITHERAPEUTICS APS 2015-10-14 — — CN disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2015-07-23 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2014-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189787-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 KDM4C 56/4885KDM5C 31/4885CYP2D6 3836/4885
US-20150203453-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM4C 56/4885KDM5C 31/4885CYP2D6 3732/4885
US-20140371195-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM4C 56/4885KDM5C 31/4885CYP2D6 3836/4885
US-20170320827-A1 INHIBITORS OF HISTONE DEMETHYLASES EHMT1, KDM1B, EHMT2 KDM4C 56/4885KDM5C 31/4885CYP2D6 3836/4885
US-10221139-B2 Inhibitors of histone demethylases EHMT1, KDM1B, EHMT2 KDM4C 56/4885KDM5C 31/4885CYP2D6 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback